Index
Module 4 • Quality & Safety
Protocol Development & Quality Improvement
66%
Data Tables
Protocol Development & Quality Improvement
Jaime Robenolt Gray ~2 min read Module 4 of 20
29
/ 44

Protocol Development and Quality Improvement

T.Policies and educational initiatives should be developed to improve opportunities identified from the MUE,

such as:

1

In-service lectures

2Newsletter publications
3

Medication alerts

4

Guideline development

5

Protocols

6

Policy and procedures

7

CPOE pathways, prescribing guides, or information or pop-up warnings

Patient Case

6

Which medication use process is best suited for an MUE?

A.Review of pharmacist notes in the electronic health record (EHR).
B.Review of accuracy of expiration dates placed on intravenous admixture products.
C.Review of vancomycin dosing and ordering of vancomycin blood concentrations.
D.Review of frequency of drug interaction warnings on the CPOE system.
V.DOCUMENTATION PROCESSES USED FOR CRITICAL CARE PHARMACY SERVICES
A.Importance of Documentation
1

Evidence of economic benefit and improvement in patient safety for clinical pharmacy services (CPS)

and critical care pharmacy services is well established. The Society of Critical Care Medicine supports

an ICU pharmacist as an essential component of the ICU team.

2Clinical pharmacy interventions that affect patient care should be documented in the electronic medical

record. Pharmacist involvement directly optimizes the use of medications, decreases drug-related costs,

prevents adverse effects, improves quality and efficacy of care, reduces mortality, shortens length of

stay (LOS), and lowers overall patient care costs.

3

Clinical interventions that can be performed by a critical care pharmacist may include but are not limited

to:

Optimization of the correct drug for the disease process (inappropriate therapy, duplication of

therapy, therapy no longer needed, etc.)

Optimization of the correct dose based on the patient’s end organ function, including continuous

renal repacement therapy adjustments, hepatic dose adjustments, and dose adjustments needed

during extracorporeal membrane oxygenation

Anticoagulation adjustment

d.Antibiotic optimization (deescalation, bug-drug mismatch, duration of therapy, etc.)

Intravenous to oral conversion

Transitions of care and/or medication reconciliation

Pharmacokinetic dosing

Adverse event management

Drug-drug or drug-disease management

Ensuring adherence to ICU medication therapy protocols (i.e., alcohol withdrawal, PADIS

management, neuromuscular blockade, etc.)

k.Drug and laboratory monitoring
Ψ΄Ψ±Ψ­ Ψ§Ω„ΩΩŠΨ―ΩŠΩˆ Ψ§Ω„ΨͺΨΉΩ„ΩŠΩ…ΩŠ β€” Ω…Ψ²Ψ§Ω…Ω†Ψ© Ω…ΨΉ Ψ§Ω„Ω€ PDF
Ψ¨Ψ―Ψ‘ Ψ§Ω„ΨͺΨ΄ΨΊΩŠΩ„ Ω…Ω†: Ψ§Ω„Ψ―Ω‚ΩŠΩ‚Ψ© 28 فΨͺΨ­ ΨΉΩ„Ω‰ YouTube